EU registry data could move from archive to research engine
Europe’s clinical trial registries now hold a scale of information that is difficult to ignore. By June 2025, the European Union’s clinical trial registry systems, the Clinical Trial Information System and the European Clinical Trial Register, contained data on nearly 55,000 clinical trials. Yet much of that information still sits at the edge of day-to-day research workflows rather than inside them, where it could shape study design, sharpen feasibility assessments, and support regulatory and policy decisions.
A Viewpoint from The Lancet Digital Health argues that this gap is no longer a technical curiosity. It is a missed opportunity for clinical research infrastructure.
Workshop stakeholders mapped three practical uses for registry data
The analysis draws on an exploratory workshop held on January 25 and 26, 2024 under the Accelerating Clinical Trials in the EU initiative. Key stakeholders from across clinical research examined how registry data might be used more effectively and where current systems fall short. The resulting synthesis organizes the use cases into three broad themes: optimizing trial design and planning, enhancing patient centricity, and strengthening evaluation of evidence for regulatory, clinical, and policy decision making.
Each theme carries a different bedside implication. Better historical trial data can reduce duplication and make protocol planning more realistic. More patient-centered registry tools can help people find studies that fit their disease, geography, and practical needs. Stronger evidence evaluation can give regulators and clinicians a broader view of what has already been studied, where uncertainty remains, and where new trials still add value.
The central message is straightforward. Registry data already exist at scale, but they are not yet being used at the level their volume would justify.
Trial planning gains power when historical data are usable
One of the clearest use cases is trial design and planning. Historical trial data can inform eligibility criteria, recruitment assumptions, comparator selection, and endpoint choice. In an environment where trial development remains expensive and often slow, the ability to interrogate prior registry data can help sponsors and investigators avoid avoidable design failures before the first participant is enrolled.
This matters because trial feasibility is often decided long before outcomes are known. If registry data are standardized and searchable, they can show which populations have been studied, which interventions have already been tested, and where evidence has become repetitive rather than useful. For multicenter development programs, that kind of intelligence can improve planning and reduce waste.
A registry that functions as a living knowledge base is more valuable than one that simply documents completed trials.
Patient centricity depends on visibility, not just registration
The workshop also identified patient centricity as a core use case. Trial registries can do more than satisfy administrative requirements; they can serve as discovery platforms for patients, families, clinicians, and advocates who need to locate studies quickly and accurately. The European Medicines Agency’s ACT EU trial map represents an initial step in that direction, offering a patient-oriented platform intended to make trial discovery easier.
For patients navigating cancer, rare disease, cardiovascular disease, or other time-sensitive conditions, access is not an abstract issue. It can determine whether a trial is found at all, whether a local site is identified in time, and whether a patient can realistically take part. Improved registry usability can therefore influence enrollment and equity, not just information flow.
Patient-facing discovery tools also carry an important public health role. When trial information is easier to locate and understand, participation is less likely to depend on insider knowledge or referral networks alone.
Evidence evaluation improves when registry data are connected across systems
The third use case reaches beyond recruitment and into the broader evaluation of clinical evidence. Registry data can help regulators, clinicians, and policymakers understand the full research footprint around a medicine or intervention. When connected with real-world data, the same records can support a richer view of effectiveness, uncertainty, and research duplication.
That potential is especially relevant in health systems that are trying to make faster decisions without sacrificing rigor. Clinical trial registries document what was planned, what was started, and in many cases what questions were asked before results enter the literature. Used well, those data can help identify unpublished or underreported studies, compare patterns across sponsors and disease areas, and anchor assessments of the collective evidence base.
The report frames this as part of a clinical trial analytics ecosystem, not a single standalone database. The distinction matters because the value rises when registry data can interact with other sources rather than remain isolated in a compliance repository.
Standardization, quality, interoperability, and transparency sit at the center
Strong consensus emerged around four enablers for better registry use: data standardization, data quality, interoperability, and transparency. Standardization ensures that equivalent information is recorded consistently across registries. Data quality supports reliable analysis and sound decision making. Interoperability allows digital health systems to exchange information seamlessly. Transparency ensures that data are accessible to the public rather than locked behind fragmented interfaces.
These are not abstract software preferences. They determine whether registry data can be compared across jurisdictions, linked with other data streams, and trusted for operational or regulatory use. Without standardization, the same concept may be captured in different ways across systems. Without interoperability, even well-curated data remain difficult to integrate. Without transparency, the public value of registration is weakened before analysis begins.
Improved registry governance therefore becomes a scientific issue as much as an informatics one.
A registry can support innovation only if people can use it
The workshop’s broader conclusion is that clinical trial registry data should support more than compliance. They can inform planning, improve patient access, strengthen evidence synthesis, and guide funding decisions if the surrounding infrastructure matures enough to support those functions.
That ambition fits the scale of the dataset already available in the EU. Nearly 55,000 registered trials represent a substantial record of biomedical experimentation, but volume alone does not create utility. Utility depends on whether the data can be found, compared, linked, and trusted.
The ACT EU initiative places this discussion in a practical frame: better use of existing registry data may help accelerate clinical trials, improve innovation, and support public health decision making. The unresolved issue is not whether the data exist. It is how quickly registry systems can become interoperable, standardized, and transparent enough to function as part of everyday research infrastructure.